Bristol licenses non-Rx drugs to Reckitt Benckiser for $482M

02/14/2013 | PharmaTimes (U.K.)

Reckitt Benckiser is paying $482 million for rights to market some of Bristol-Myers Squibb's nonprescription medications in Latin America. The three-year deal includes the painkiller Tempra, the antacid Picot, and cough and cold drug Naldecon. After three years, Reckitt Benckiser will be given the option to acquire legal rights and intellectual property for the treatments.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA